Blueprint Medicines (BPMC) Reports Q2 Loss of $0.62/Share

Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($0.62), versus ($0.86) reported last year. Revenue for the quarter came in at $41.44 million, versus $5.89 million reported last year.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• KB Home (KBH) Tops Q3 EPS by 16c
• KB Home (KBH) PT Lowered to $50 at RBC Capital